Category: Intellectual property
-
$2 Billion Biotech Licensing Deal Cancelled
A licensing deal with a potential value of more than $2 billion between two biotechnology companies for a new breast cancer drug was cancelled on Friday.
-
Shire Licensing Dry Eye Disease Treatment in $535M Deal
An experimental drug for treating dry eye disease, a common disorder affecting older individuals, is being licensed by international pharmaceutical company Shire plc.
-
Start-Up Licensing Flexible Genome-Editing Technology
A start-up biotechnology company is licensing techniques from two universities that make genome editing more flexible and better control gene expression.
-
NIH Funds Seen Boosting Industry Patents
An analysis of grants issued by National Institutes of Health shows a large percentage of those grants, directly or indirectly, result in patented technologies in industry.
-
Univ. of California to Gain European Crispr-Cas9 Patent
A patent dispute among top research universities took another turn, as the European Patent Office announced its intention to grant a patent to University of California for its genome editing techniques.
-
Univ. Spin-Off Developing Non-Toxic Bedbug Killer
Research from a lab at Pennsylvania State University led to a technology for controlling bedbug infestations with natural enemies that are harmless to humans.
-
Allergan to Option Gene Editing for Eye Diseases
International drug maker Allergan is gaining access to treatments for inherited eye diseases being developed by Editas Medicine, a spin-off enterprise from MIT and Harvard.
-
Process Converts Food Waste to Auto Tire Materials
Agricultural scientists in Ohio are developing a process for converting common food waste into materials used in car tires, and filed a patent for these techniques.
-
Duchenne Gene-Editing Company Launched, Raising $5M
A biotechnology start-up is applying a process for editing-out disease-causing mutations to correct the inherited disorder Duchenne muscular dystrophy.
-
Nuclear Cancer Therapy Company Launches, Raises $25M
A new company developing cancer therapies combining nuclear radiation and synthetic antibodies is starting up in Hamilton, Ontario.